t
On 16 July 2026, David Hallas, Chief Executive Officer of ECO Animal Health Group plc, purchased 22,346 ordinary shares at 89.5 pence per share. Following this transaction, Mr. Hallas holds 225,387 ordinary shares, representing approximately 0.33 per cent of the Company's issued share capital.
| Date | 16 Jul 2026 |
| Time | 14:34:18 |
| Category | Director/PDMR dealings |
| ID | 6942M |
16 July 2026
ECO Animal Health Group plc
("ECO" or the "Company")
CEO Share Purchase
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that on 16 July 2026 David Hallas, Chief Executive Officer, purchased 22,346 ordinary shares in the Company ("Ordinary Shares") at 89.5 pence per Ordinary Share.
Following this, David Hallas holds 225,387 Ordinary Shares, representing approximately 0.33 per cent. of the Company's issued share capital.
The notification below, provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group's proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO's pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in June 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group's website or LinkedIn page for further information.
PDMR Notification
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
||||||||||
|
a. |
Name |
David Hallas |
|||||||||
|
2. |
Reason for the notification |
||||||||||
|
a. |
Position/status |
Chief Executive Officer
|
|||||||||
|
b. |
Initial notification /Amendment
|
Initial notification |
|||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a. |
Name |
Eco Animal Health Group Plc |
|||||||||
|
b. |
LEI |
2138009XN9DJ3YP70B55 |
|||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary shares of 5p each.
GB0032036807
|
|||||||||
|
b. |
Nature of the transaction |
Purchase of Ordinary Shares |
|||||||||
|
c. |
Price(s) and volume(s) |
|
|||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
|
|||||||||
|
e. |
Date of the transaction |
16 July 2026 |
|||||||||
|
f. |
Place of the transaction |
XLON - LONDON STOCK EXCHANGE - AIM |
|||||||||